Nitrobenzylthioinosine: an in vivo inhibitor of pig erythrocyte energy metabolism.
The potential role of plasma nucleosides as metabolic energy substrates for pig erythrocytes, which are impermeable to glucose, was investigated in vivo by infusion of anesthetized pigs with nitrobenzylthioinosine phosphate (NBMPR-P), a soluble prodrug form of the specific nucleoside transport inhibitor, nitrobenzylthioinosine. NBMPR-P administration (1 or 10 mg X kg-1 X h-1) led to complete in vivo blockade of erythrocyte nucleoside transport activity and was associated with a dramatic decrease in the erythrocyte [ATP]-to-[ADP] ratio from 11.4 at time 0 to 2.9 after 4 h (mean results from 3 animals). Plasma inosine concentrations increased progressively from 2-4 microM at time 0 to 20-70 microM after 4 h of drug administration. In contrast, plasma adenosine concentrations remained less than 0.4 microM in all samples. These data suggest that pig erythrocytes utilize plasma inosine as their physiological energy substrate.
D000244:Adenosine Diphosphate / Q000097:blood; D000255:Adenosine Triphosphate / Q000097:blood; D000345:Affinity Labels / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D004734:Energy Metabolism / Q000187:drug effects*; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism*; D007288:Inosine / Q000031:analogs & derivatives* / Q000097:blood / Q000502:physiology*; D013552:Swine / Q000097:blood*; D013868:Thioinosine / Q000031:analogs & derivatives* / Q000494:pharmacology; D013873:Thionucleotides / Q000494:pharmacology
D000345:Affinity Labels; D001786:Blood Glucose; D013873:Thionucleotides; D013868:Thioinosine; D007288:Inosine; D000244:Adenosine Diphosphate; C028318:nitrobenzylthioinosine 5'-monophosphate; D000255:Adenosine Triphosphate; C001789:4-nitrobenzylthioinosine